Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats

European Journal of Pharmacology

Volumn 380, Issue 2-3, 1999, Pages 101-107

  Kosasa, Takashi ^a   Kuriya, Yuka ^a   Matsui, Kenji ^a   Yamanishi, Yoshiharu ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Acetylcholine; Acetylcholinesterase inhibitor; Donepezil hydrochloride; E2020; ENA 713; Microdialysis; Tacrine

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ADMINISTRATION, ORAL; ANIMALS; BRAIN; CARBAMATES; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SPACE; HIPPOCAMPUS; INDANS; MALE; PHENYLCARBAMATES; PIPERIDINES; RATS; RATS, WISTAR; TACRINE;

EID: 0032837398     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00545-2     Document Type: Article

References (20)

1. Anand R., Gharabawi G. Clinical development of exelone (ENA-713): the Adena programme. J. Drug Dev. Clin. Pract. 8:1996;9-14.
2. Beermann B. Side effects of long-acting cholinesterase inhibitor. Acta Neurol. Scand. 149:1993;53-54.
3. Giacobini E., Zhu X.-D., Williams E., Sherman K.A. The effect of the selective reversible acetylcholinesterase inhibitor, E2020, on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology. 35:1996;205-211.
4. Ishii Y., Kojima J., Ikeda N., Kawashima K. Effect of NIK-247 on basal concentrations of extracellular acetylcholine in the cerebral cortex of conscious, freely moving rats. Jpn. J. Pharmacol. 66:1994;289-293.
5. Kawashima K., Sato A., Yoshizawa M., Fujii T., Fujimoto K., Suzuki T. Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 350:1994;523-528.
6. Messamore E., Warpman U., Ogane N., Giacobini E. Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex. Neuropharmacology. 32:1993;745-750.
7. Ogura H., Kosasa T., Araki S., Yamanishi Y., Yamatsu K. Behavioral study of E2020, a novel centrally acting acetylcholinesterase inhibitor. Soc. Neurosci. Abstr. 14(1):1988;60.
8. Ohara T., Tanaka K., Fukaya H., Demura N., Iimura A., Seno N. SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats. Behav. Brain Res. 83:1997;229-233.
9. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd edn. 1986;Academic Press, Sydney.
10. Rogers S.L., Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur. Neuropsychopharmacol. 8:1998;67-75.
11. Rogers S.L., Yamanishi Y., Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. Becker R., Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;314-320 Birkhäuser, Boston, MA.
12. Rogers S.L., Friedhoff L.T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia. 7:1996;293-303.
13. Rogers S.L., Doody R.S., Mohs R., Friedhoff L.T. Donepezil improves cognitive and global function in Alzheimer' disease: a 15-week double-blind, placebo-controlled study. Arch. Intern. Med. 158:1998;1021-1031.
14. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50:1998;136-145.
15. Sherman K.A. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. Becker R., Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;321-328 Birkhäuser, Boston, MA.
16. Sugimoto H., Iimura Y., Yamanishi Y., Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38:1995;4821-4829.
17. Taylor P. Anticholinesterase agents. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th edn. 1996;161-176 McGraw-Hill, New York.
18. Thomsen T., Kewitz H., Pleul O. A suitable method to monitor inhibition of cholinesterase activities in tissues as induced by reversible enzyme inhibitors. Enzyme. 42:1989;219-224.
19. Weinstock M., Razin M., Chorev M., Enz A. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J. Neural Transm. 43:1994;219-225.
20. Yamanishi Y., Araki S., Kosasa T., Ogura H., Yamatsu K. Neurochemical studies of E2020, a novel centrally acting acetylcholinesterase inhibitor. Soc. Neurosci. Abstr. 14(1):1988;59.